Data and publications

Published articles

Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, Alimonti A, Bettini E, Mangano RM, Wessel T, de Somer M, Caron J, Vitolo OV, DiGuglielmo G, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Folli F, Traversa S, Inturrisi C, Manfredi P

REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase2a randomized double-blind trial

Am J Psychiatry. 2022 Feb;179(2):122-131.
doi: 10.1176/appi.ajp.2021.21020197. Epub 2021 Dec 22.

De Martin S, Gabbia D, Folli F, Bifari F, Fiorina P, Ferri N, Stahl S, Inturrisi C, Pappagallo M, Traversa S, Manfredi P

REL-1017 (Esmethadone) increases circulating BDNF levels in healthy subjects of a Phase 1 clinical study

Frontiers in Pharmacology. 2021;12:973-978.
https://doi.org/10.3389/fphar.2021.671859.

Bernstein G, Davis K, Mills C, Wang L, McDonnell M, Oldenhof J, Inturrisi C, Manfredi P, Vitolo O

Characterization of the safety and pharmacokinetic profile of d-methadone, a novel N-methyl-D-aspartate receptor antagonist in healthy, opioid-naive subjects: Results of two Phase 1 studies

Journal of Clinical Psychopharmacology. 2019;39(3):226-237.
https://doi.org/10.1097/jcp.0000000000001035.

Bifari F, Pappagallo M, Bleavins M, Traversa S, Folli F, Manfredi P

REL-1017 (Esmethadone), a novel NMDAR blocker for the treatment of MDD is not neurotoxic in Sprague-Dawley rats

Frontiers in Pharmacology. 2022. 13:863959.
https://doi.org/10.3389/fphar.2022.863959.

Hanania T, Manfredi P, Inturrisi C, Vitolo O

The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats

Exp Clin Psychopharmacol. 2020;28(2):196-201.
https://doi.org/10.1037/pha0000310.

Foga├ža M, Fukumoto K, Franklin T, Liu R, Duman C, Vitolo O, Duman R

N-methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects

Neuropsychopharmacology. 2019;44(13):2230-2238.
https://doi.org/10.1038/s41386-019-0501-x.

Congress presentations

Henningfield J, Apseloff G, Gorodetzky C, Pappagallo M, Shram M, De Martin S, Fant R, Vocci F, Sapienza F, Kosten T, Huston J, Buchhalter A, Ashworth J, Lanier R, Folli F, Traversa S, Inturrisi C, Manfredi P

No meaningful opioid abuse liability of REL-1017 (esmethadone; d-methadone), a rapid-acting antidepressant in clinical development: a human abuse potential study

American College of Neuropsychopharmacology (ACNP) 60th Annual Meeting 2021
Neuropsychopharmacol. 46, 218-368, P315 (2021).
https://doi.org/10.1038/s41386-021-01237-6.